AbCellera
intellectual property or global intellectual property portfolio with foundational patents applications owned or exclusively licensed patent families tit immune rep sie foundational claims on high throughput single cell secretion assays with application to antibody discovery clone selection via elt | AbCellera
Company
Deck Type
IPO
Deck date
December 2020
Slide
35 of 38
Related slides by other companies
Mergers and Acquisitions
June 2023
Investor Presentation
September 2022
Other recent decks by AbCellera
Investor Presentation
February 2024
Investor Conference
January 2024
Results
November 2023
Investor Presentation
November 2023
Search Thousands of Presentations by World Leading Companies